Researchers investigate HIV treatment efficacy and immune recovery

New research highlights both advancements and challenges in managing HIV. A study published in Nature Microbiology by researchers at the University of California, Davis, explores a potential breakthrough using an experimental bispecific antibody. In trials involving rhesus macaques infected with SIV, a relative of HIV, the antibody targeted the CCR5 receptor and the CD3 protein on T lymphocytes. While standard antiretroviral therapy failed to prevent viral rebound after treatment cessation, some macaques treated with the bispecific antibody showed no viral recurrence for several months, with one subject remaining undetectable for four years.

Complementary research from Radboudumc in the Netherlands indicates that successful HIV treatment does not guarantee uniform immune system recovery. Studies led by Adriana Navas found significant differences in immunological responses and biological aging markers among patients. Even when viral replication is effectively suppressed by antiretroviral therapy, some individuals fail to achieve proper immune reconstitution, potentially increasing their vulnerability to age-related diseases.